Jue Yuan

Jue Yuan

Auto-generated profile, based on publicly available information

Jue Yuan

Departments of Pathology and Neurology, Case Western Reserve University School of Medicine, Cleveland, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
Christina Doriana OrrúChristina Doriana Orrú
Christina Doriana Orrú
JYJue Yuan
Jue Yuan
BABrian S. Appleby
Brian S. Appleby
BLBaiya Li
Baiya Li
YLYu Li
Yu Li
WZWen-Quan Zou
Wen-Quan Zou
Sporadic Creutzfeldt-Jakob disease (sCJD), the most common human prion disease, is transmissible through iatrogenic routes due to abundant infectious prions [misfolded forms of the prion protein (PrPSc)] in the central nervous system (CNS). Some epidemiological studies have associated sCJD risk with non-CNS surgeries. We explored the potential prion seeding activity and infectivity of skin from sCJD patients. Autopsy or biopsy skin samples from 38 patients [21 sCJD, 2 variant CJD (vCJD), and 15 non-CJD] were analyzed by Western blotting and real-time quaking-induced conversion (RT-QuIC) for PrPSc. Skin samples from two patients were further examined for prion infectivity by bioassay using two lines of humanized transgenic mice. Western blotting revealed dermal PrPSc in one of five deceased sCJD patients and one of two vCJD patients. However, the more sensitive RT-QuIC assay detected prion seeding activity in skin from all 23 CJD decedents but not in skin from any non-CJD control individuals (with other neurological conditions or other diseases) during blinded testing. Although sCJD patient skin contained ~103- to 105-fold lower prion seeding activity than did sCJD patient brain tissue, all 12 mice from two transgenic mouse lines inoculated with sCJD skin homogenates from two sCJD patients succumbed to prion disease within 564 days after inoculation. Our study demonstrates that the skin of sCJD patients contains both prion seeding activity and infectivity, which raises concerns about the potential for iatrogenic sCJD transmission via skin.

13 May 2021 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
MDMingxuan Ding
Mingxuan Ding
KTKenta Teruya
Kenta Teruya
WZWeiguanliu Zhang
Weiguanliu Zhang
HLHae Weon Lee
Hae Weon Lee
JYJue Yuan
Jue Yuan
WZWen-Quan Zou
Wen-Quan Zou
Previous studies have revealed that the infectious scrapie isoform of prion protein (PrPSc) harbored in the skin tissue of patients or animals with prion diseases can be amplified and detected through the serial protein misfolding cyclic amplification (sPMCA) or real-time quaking-induced conversion (RT-QuIC) assays. These findings suggest that skin PrPSc-seeding activity may serve as a biomarker for the diagnosis of prion diseases; however, its utility as a biomarker for prion therapeutics remains largely unknown. Cellulose ethers (CEs, such as TC-5RW), widely used as food and pharmaceutical additives, have recently been shown to prolong the lifespan of prion-infected mice and hamsters. Here we report that in transgenic (Tg) mice expressing hamster cellular prion protein (PrPC) infected with the 263K prion, the prion-seeding activity becomes undetectable in the skin tissues of TC-5RW-treated Tg mice by both sPMCA and RT-QuIC assays, whereas such prion-seeding activity is readily detectable in the skin of untreated mice. Notably, TC-5RW exhibits an inhibitory effect on the in vitro amplification of PrPSc in both skin and brain tissues by sPMCA and RT-QuIC. Moreover, we reveal that TC-5RW is able to directly decrease protease-resistant PrPSc and inhibit the seeding activity of PrPSc from chronic wasting disease and various human prion diseases. Our results suggest that the level of prion-seeding activity in the skin may serve as a useful biomarker for assessing the therapeutic efficacy of compounds in a clinical trial of prion diseases and that TC-5RW may have the potential for the prevention/treatment of human prion diseases.

1 January 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JYJue Yuan
Jue Yuan
MKMichael Kinter
Michael Kinter
JMJohn McGeehan
John McGeehan
George PerryGeorge Perry
George Perry
GKGeoff Kneale
Geoff Kneale
WZWen-Quan Zou
Wen-Quan Zou

25 March 2010
Verified
Book Chapter
Closed access
SNS. Notari
S. Notari
Xinxin XiaoXinxin Xiao
Xinxin Xiao
MSM. Shimoji
M. Shimoji
JYJ. Yuan
J. Yuan
HBH. Bi
H. Bi
WZWen-Quan Zou
Wen-Quan Zou